Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-7

  Eltabbakh, Mohamed ^a   Zaghla, Hassan ^a   Abdel Razek, Wael ^a   Elshinnawy, Hassan ^a   Ezzat, Sameera ^b   Gomaa, Asmaa ^a   Waked, Imam ^a  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Alpha fetoprotein; Cost effectiveness; Hepatocellular carcinoma; Limited resources; Screening; Ultrasonography

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; PROTHROMBIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER INCIDENCE; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; CHILD PUGH SCORE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SURVEILLANCE; EGYPT; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PORTAL VEIN THROMBOSIS; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; THROMBOCYTE COUNT; COMPLICATION; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ECHOGRAPHY; ECONOMICS; LIVER CIRRHOSIS; LIVER TUMOR; MASS SCREENING; MIDDLE AGED; PROCEDURES;

ADULT; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EGYPT; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MASS SCREENING; MIDDLE AGED;

EID: 84920139418     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0432-7     Document Type: Article

References (30)

1. WHO: International Agency for Research on Cancer: PRESS RELEASE No 224. Lyon/London, 3 Feb 2014. http://nvhr.org/sites/default/files/WHO%20Press%20Release%20224.pdf. Accessed 5 Mar 2014.
2. Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. J Hepatol. 2000;33:1006–8.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
4. European Association For The Study Of The Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
5. Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350–91.
6. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–74.
7. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular car-cinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29:339–64.
8. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–6.
9. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Impact of surveillance on survival of patients with initial hepatocellular carcinoma: a study from Japan. Clin Gastroenterol Hepatol. 2006;4:1170–6.
10. Coon JT, Rogers G, Hewson P, Wright D, Anderson R, Cramp M, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007;11:1–206.
11. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686–93.
12. Levy I, Greig PD, Gallinger S, Langer B, Sherman M. Resection of hepatocellular carcinoma without preoperative tumor biopsy. Ann Surg. 2001;234:206–9.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.
14. Llovet J, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, et al. Natural history of untreated nonsurgical HCC: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7.
15. Mathers C, Vos T, Stevenson C 1999. The burden of disease and injury in Australia. AIHW cat. no. PHE 17. Canberra: AIHW. http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=6442459196.
16. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings—the case of Cote d’Ivoire. N Engl J Med. 2006;355:1141–53.
17. WHO: Cost-effectiveness thresholds. http://www.who.int/choice/costs/CER_thresholds/en/. Accessed 7 July 2014.
18. Gomaa A, Rewisha E, Saleh S, Waked I. Changing presenting features of hepatocellular carcinoma in Egyptian patients. 7th International Liver Cancer Association (ILCA) Annual Conference 2013, September 13–15; Washington, DC, USA: Abstract P-077.
19. Klabunde C, Brown M, Ballard-Barbash R. cancer screening—United States 2012, morbidity and mortality weekly report: 2012, vol 61, no 3. www.cdc.gov. Accessed 10 July 2014.
20. Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425–32.
21. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.
22. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with HCC in the United States. J Clin Gastroenterol. 2002;35:266–9.
23. Davila J, Morgan R, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the rising incidence of HCC: a population-based study. Gastroenterology. 2004;127:1372–80.
24. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61–6.
25. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child’s A cirrhosis: a 8 year prospective study by ultrasound and alphafetoprotein. J Hepatol. 1994;21:1029–34.
26. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48:251–9.
27. Leykum LK, El-Serag HB, Cornell J, Papadopoulos KP. Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival. Clin Gastroenterol Hepatol. 2007;5:508–12.
28. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.
29. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Metaanalysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.
30. Sherman M, Peltekian K, Lee C. Screening for HCC in chronic carriers of hepatitis B virus: incidence and prevalence of HCC in a North American urban population. Hepatology. 1995;22:432–8.